Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.55 |
| ▸ | GRM5 | P41594 | 6/20 | 0.53 |
| ▸ | RAB9A | P51151 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.50 |
| ▸ | NPC1 | O15118 | 7/20 | 0.50 |
| ▸ | PKM | P14618 | 6/20 | 0.50 |
| ▸ | TP53 | P04637 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KLF5 | Q13887 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1997514 | 0.87 | PTGDR2 (0.67) | PTGDR2RAB9ASMN1; SMN2NPC1TP53 | |
| SCHEMBL2002169 | 0.83 | PTGDR2 (0.68) | PTGDR2RAB9ASMN1; SMN2NPC1TP53 | |
| SCHEMBL1993359 | 0.83 | PTGDR2 (0.55) | PTGDR2RAB9ASMN1; SMN2NPC1TP53 | |
| SCHEMBL1995943 | 0.82 | NPC1 (0.63) | PTGDR2RAB9ASMN1; SMN2NPC1TP53 | |
| SCHEMBL4197833 | 0.82 | NPC1 (0.73) | GRM5RAB9ASMN1; SMN2NPC1PKM | |
| SCHEMBL1992646 | 0.82 | PTGDR2 (0.53) | PTGDR2RAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL1996239 | 0.81 | PTGDR2 (0.56) | PTGDR2RAB9ASMN1; SMN2NPC1TP53 | |
| SCHEMBL1993837 | 0.81 | PTGDR2 (0.55) | PTGDR2GRM5RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL1995007 | 0.80 | PTGDR2 (0.53) | PTGDR2RAB9ASMN1; SMN2NPC1PKM | |
| SCHEMBL1996328 | 0.80 | PTGDR2 (0.56) | PTGDR2RAB9ASMN1; SMN2NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269763-A1 | CRTH2 receptor ligands for medicinal uses | 7TM PHARMA A/S (DK) | 2011-11-03 | — | — | US | disclosed |
| US-20110269763-A1 | CRTH2 receptor ligands for medicinal uses | 7TM PHARMA A/S (DK) | 2011-11-03 | — | — | US | disclosed |
| US-8022063-B2 | CRTH2 receptor ligands for medicinal uses | 7TM PHARMA A/S (DK) | 2011-09-20 | — | — | US | disclosed |
| US-8022063-B2 | CRTH2 receptor ligands for medicinal uses | 7TM PHARMA A/S (DK) | 2011-09-20 | — | — | US | disclosed |
| US-8022063-B2 | CRTH2 receptor ligands for medicinal uses | 7TM PHARMA A/S (DK) | 2011-09-20 | — | — | US | disclosed |
| EP-2336113-A1 | CRTH2 Receptor Ligands for Medical Use | 7TM Pharma A/S (DK) | 2011-06-22 | — | — | EP | disclosed |
| US-20090099189-A1 | CRTH2 Receptor Ligands For Medicinal Uses | 7TM PHARMA A/S (DK) | 2009-04-16 | — | — | US | disclosed |
| US-20090099189-A1 | CRTH2 Receptor Ligands For Medicinal Uses | 7TM PHARMA A/S (DK) | 2009-04-16 | — | — | US | disclosed |
| US-20090099189-A1 | CRTH2 Receptor Ligands For Medicinal Uses | 7TM PHARMA A/S (DK) | 2009-04-16 | — | — | US | disclosed |
| EP-1758579-A1 | CRTH2 RECEPTOR LIGANDS FOR MEDICINAL USES | 7TM Pharma A/S (DK) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005115382-A1 | CRTH2 RECEPTOR LIGANDS FOR MEDICINAL USES | 7TM PHARMA A/S (DK) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099189-A1 | CRTH2 Receptor Ligands For Medicinal Uses | HRH1, HRH2, HRH3 | PTGDR2 70/4885GRM5 440/4885RAB9A 2702/4885 |
| US-20110269763-A1 | CRTH2 receptor ligands for medicinal uses | HRH1, HRH2, HRH4 | PTGDR2 61/4885GRM5 427/4885RAB9A 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.